cisplatin, nivolumab
Nivolumab yakasanganiswa necisplatin uye gemcitabine inotenderwa neUSFDA kune isingagadziriswe kana metastatic urothelial carcinoma.
March 2024: The Food and Drug Administration has granted approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with cisplatin and gemcitabine as the initial treatment for adult patients with unres..
Pembrolizumab, USFDA
Enfortumab vedotin-ejfv ine pembrolizumab inotenderwa neUSFDA kune yemuno advanced kana metastatic urothelial carcinoma.
Feb 2024: The Food and Drug Administration has sped up the approval process for two drugs, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck). These drugs are meant to treat people with locally ..
Bristol Myers squibb, CHECKMATE-274, nivolumab, Wonderful, Urothelial carcinoma
Nivolumab yakagamuchirwa neDFA kuti ishandiswe seanobatsira kurapwa kweurothelial carcinoma
Nyamavhuvhu 2021: Nivolumab (Opdivo, Bristol-Myers Squibb Co) yakagamuchirwa neKudya neDrug Administration kuti irapwe kurapwa kwevarwere vane urothelial carcinoma (UC) vari panjodzi huru yekudzokazve zvichitevera rad ..
Astellas Pharma US, NCT03474107, Padcev, Muedzo EV-301
Iyo FDA yakapa enfortumab vedotin-ejfv mvumo yekurapwa kwenzvimbo yepamusoro kana metastatic urothelial carcinoma
Nyamavhuvhu 2021: Enfortumab vedotin-ejfv (Padcev, Astellas Pharma US, Inc.), Nectin-4-inotungamirwa antibody uye microtubule inhibitor mubatanidzwa, yakatenderwa neKudya neDrug Administration kune vanhu vakuru varwere vane munharaunda adv ..
Immunomedics Inc., MUC, platinum ine chemotherapy, yakagadzirirwa kufa receptor-1, sacituzumab govitecan, Trodelvy, mukombe
Sacituzumab govitecan inogamuchira mvumo nekukurumidza kubva kune iyo FDA yekenza yepamusoro yeurothelial cancer
Nyamavhuvhu 2021: Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) yakapihwa mvumo yekukurumidza neKudya neDrug Administration kune varwere vane gomarara repamberi kana metastatic urothelial cancer (mUC) avo vakambogamuchira ..